促甲状腺激素抑制疗法在分化型甲状腺癌治疗中的作用  

Value of Thyroid Stimulating Hormone Inhibition Therapy in Differentiated Thyroid Carcinoma

作　　者：马峻峰[1] 唐波[2] 李铁汉[2] 张捷[2] 

机构地区：[1]昆明医学院第二附属医院肿瘤科,昆明650101 [2]昆明医学院第二附属医院普外科,昆明650101

出　　处：《中国普外基础与临床杂志》2009年第5期348-350,355,共4页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的探讨促甲状腺激素(TSH)抑制疗法在分化型甲状腺癌患者术后治疗中的作用。方法106例分化型甲状腺癌行全或近全甲状腺切除术的患者术后分别行TSH抑制治疗(TSH抑制治疗组)或甲状腺素替代治疗(甲状腺素替代治疗组),通过Wilcoxon(Gehan比分)检验分析比较2组患者的术后无复发和(或)无转移率。结果TSH抑制治疗组3年、5年及10年的无复发和(或)无转移率分别为98.31%、92.41%及75.45%,甲状腺素替代治疗组分别为93.57%、84.18%及52.06%,前组明显高于后组(P=0.0465)。结论TSH抑制疗法是分化型甲状腺癌患者行全或近全甲状腺切除术后的有效治疗手段。Objective To investigate the value of thyroid stimulating hormone （TSH） inhibition therapy in postoperative patients with differentiated thyroid carcinoma. Methods One hundred and six patients with differentiated thyroid carcinoma after total or near total thyroidectomy were divided into two groups： TSH inhibition therapy group and thyroid hormone replacement therapy group. The non-recurrence and （or） non-metastasis rate in two groups was analyzed retrospectively by Wilcoxon statistical analysis. Results The non-recurrence and （or） non-me- tastasis rate of 3-, 5- and 10--year in TSH inhibition therapy group were 98.31%, 92.41% and 75.45% respectively, and were higher than those （93.57 %, 84.18 % and 52.06 % respectively） in thyroid hormone replacement therapy group （P=0. 046 5）. Conclusion TSH inhibition therapy after total or near-total thyroidectomy may be an essential treatment for differentiated thyroid carcinoma patients.

关 键 词：分化型甲状腺癌 促甲状腺激素抑制疗法 甲状腺素替代治疗 复发率 转移率 

分 类 号：R736.1[医药卫生—肿瘤] R653[医药卫生—临床医学]